Kevindol (ketorolac tromethamine) is an effective non-opioid analgesic generally applied in clinical contexts where short-term, supportive symptomatic assistance is needed. It is commonly used in situations involving moderately severe acute pain that is typically linked to intense discomfort. This medication is considered relevant for supporting therapeutic management of distressing symptoms and associated physical manifestations that create noticeable interference with daily stability.

---

Symptomatic Relief and Usage

This medication plays a role in symptomatic management by helping to ease pronounced, sharp pain and supports symptomatic relief in conditions presenting with acute episodes. It is relevant in therapeutic areas involving heightened responses, commonly used across conditions characterized by periods of heightened symptoms, including postoperative pain, discomfort from acute musculoskeletal trauma, and dysmenorrhea.

The key benefit is the provision of supportive symptomatic relief that helps patients cope more steadily with difficult episodes. The supportive relief for pain and inflammation also helps ease the overall symptom burden.

---

Quick Facts

Quick Fact: Relief for Acute Discomfort Kevindol is typically used for managing short-term, intense discomfort, and assists with managing symptoms during episodes of heightened physical discomfort and inflammation.

Regulatory References

1. NIH DailyMed label for Ketorolac Tromethamine

The eligibility profile for Kevindol (ketorolac tromethamine) is highly restricted due to the serious risks associated with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), as defined by government regulatory agencies (e.g., FDA, EMA). Use is typically permitted only for adults (generally ge 16 or 18 years) for short-term pain management and must not exceed five days in total.

Populations for Whom Use is Contraindicated

Kevindol is absolutely contraindicated (prohibited) in patients with the following conditions, among others:

• Gastrointestinal Risk: Active peptic ulcer disease, recent GI bleeding or perforation, or a history of either condition.
• Bleeding Risk: Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, or any high risk of bleeding, including for prophylactic analgesia before major surgery or in the setting of CABG surgery.
• Organ Failure: Advanced renal impairment or severe heart/hepatic failure.
• Hypersensitivity: Known allergic reactions to ketorolac, aspirin, or any other NSAID.

Age-Related and Condition-Specific Restrictions

• Pediatric Patients: Use is not established and generally contraindicated for children under 16 or 17 years of age, depending on the regulatory document.
• Older Adults: Patients ge 65 years of age require special consideration and a restricted maximum daily dose due to increased sensitivity and risk.
• Renal Impairment: Contraindicated in advanced renal disease; patients with mild-to-moderate impairment or those under 50 kg must use a reduced maximum dose.
• Pregnancy/Lactation: Use is contraindicated during labor, delivery, and lactation, and must be avoided from 30 weeks gestation onward.

The official regulatory documentation for Kevindol (ketorolac tromethamine) specifies several critical interactions, categorized primarily by pharmacodynamic risk and effects on drug clearance.

Contraindicated Combinations

Co-administration is contraindicated with several medicinal products due to the documented risk of serious cumulative effects. These combinations include Aspirin or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Probenecid, Pentoxifylline, and any other Ketorolac formulation (oral, injectable, or nasal).

Interactions Affecting Exposure and Clearance

Kevindol may alter the clearance of co-administered drugs. Regulatory labeling states that the combination can result in increased plasma lithium levels and decreased lithium clearance, raising the potential for toxicity. Similarly, Kevindol increases Methotrexate toxicity by formally decreasing its renal clearance. The combination with Salicylates may lead to a potential twofold increase in unbound Kevindol plasma levels due to reduced protein binding.

Pharmacodynamic Risk and Cautions

Significant caution is required when co-administering with other substances that affect hemostasis. Concomitant use with anticoagulants (such as Warfarin) or antiplatelet agents increases the documented risk of serious bleeding. The risk of gastrointestinal ulcers and bleeding is also increased when co-administered with oral corticosteroids or Alcohol. Furthermore, Kevindol may impair the effect of Diuretics and ACE Inhibitors or ARBs, potentially increasing the risk of renal impairment, especially in volume-depleted patients.

Population-Specific Notes

For Elderly Patients, regulatory documents note that the drug may be cleared more slowly, increasing sensitivity to interaction-related adverse effects. A procedural restriction applies to the ophthalmic solution: it requires a 5-minute separation from other topical ophthalmic medications.

Inhibition of Prostaglandin Synthesis

Kevindol (ketorolac tromethamine) exerts its effect by acting as a non-selective inhibitor of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This action blocks the conversion of arachidonic acid into prostaglandins—chemical mediators that are fundamental to nociceptive signaling and inflammatory responses. This key molecular step profoundly limits the chemical signals that initiate and sustain exaggerated eicosanoid activity.

---

Modulation of Central and Peripheral Nociception

The drug's mechanism leads to a decrease in pro-inflammatory mediators both at the site of tissue distress (periphery) and within the central nervous system (spinal cord). This dual action decreases the sensitization of peripheral nociceptors while simultaneously limits the central amplification of nociceptive signals. This integrated, multi-level pathway adjustment contributes to a disruption of the nociceptive signal transmission cascade.

---

Inherent Mechanistic Trade-offs

The non-selective nature of the enzyme inhibition inherently extends to constitutive COX-1 functions, leading to two specific physiological consequences: the reversible block of Thromboxane A2 synthesis in platelets and the reduction of protective prostaglandins in the gastric mucosa and kidneys. This alteration of constitutive eicosanoid regulation is an unavoidable consequence of the core mechanism.

Kevindol (ketorolac tromethamine) administration is governed by a highly controlled protocol focusing on short-term use, defined across multiple official routes: intravenous (IV) injection, intramuscular (IM) injection, oral tablet, and intranasal spray. The maximum duration for the combined use of all systemic formulations must strictly not exceed five days for any single course of treatment.

The medication's usage follows a mandated sequential pattern: the oral tablet is designated solely as continuation therapy following initial parenteral (IV or IM) administration; it is never to be given as a starting dose. Standard adult dosing (for patients ge 50 kg and < 65 years) for IV or IM multiple-dose regimens typically involves 30 mg every 6 hours, with a total maximum daily limit of 120 mg. Once transitioned, the oral maintenance dose is 10 mg every 4 to 6 hours, not to exceed 40 mg per day.

Mandatory dose adjustments are specified for special patient populations. A reduced maximum daily dose is required for patients ge 65 years of age, those weighing < 50 kg, or individuals with impaired kidney function; their maximum combined injectable dose must be limited to 60 mg per day. Procedural requirements also dictate that the oral tablet should be taken with food or an antacid, and IV bolus injections must be administered over a period of no less than 15 seconds. These explicit instructions define the standardized and permissible application of the medicine.

Research Evidence / Overview of Studies for Kevindol (Ketorolac Tromethamine)

Evidence for Use in Acute Pain After Surgery

The research on Kevindol primarily addresses short-term pain experienced by Adults after surgery. The evidence consists mainly of short-term Randomized Controlled Trials (RCTs) and large meta-analyses. Researchers studied outcomes related to physical discomfort by measuring patient-reported perceived discomfort using standardized scales. They also monitored the total amount of rescue analgesics requested by patients during the observation period. Studies report how symptoms evolved in the observed populations, providing insight into short-term changes.

Evidence for Use in Acute Pain from Musculoskeletal Trauma

Research examined the use of Kevindol in cases of acute pain resulting from injuries to the muscles or bones. Studies explored short-term symptom patterns in Adults in acute care settings. Outcomes monitored included short-term changes in pain intensity scores and the need for early supplementary analgesia. Research highlights changes measured during the study period, helping to contextualize how patients reported their experience.

Evidence for Use in Menstrual Pain (Dysmenorrhea)

Kevindol was studied for conditions characterized by fluctuating or episodic manifestations, such as primary dysmenorrhea, through randomized trials with Adult women. The studies monitored outcomes related to physical discomfort, specifically tracking patient-reported discomfort levels and the intensity of cramping. Evidence is limited to the acute symptomatic period and provides context but not individual predictions for cyclical pain patterns.

Duration of Studies and Limits of Follow-up Data

The research conducted for Kevindol reflects its indication for short-term use, meaning follow-up durations were limited, typically up to five days. Studies help show what has been observed so far, but there is limited information for long-term outcomes that might extend beyond this window. The research does not provide insight into the durability of responses, and long-term effects are not fully established.

Evidence in Special Populations

Research has evaluated Kevindol in patient groups such as Older Adults and children. Studies suggested that the agent may stay in the body longer in older adults compared to younger adults. For children, the research base is smaller, and its use has been subject to varied evidence quality; clinical practice reflects uncertainty, and certainty remains low in this area.

What Research Gaps and Uncertainty Still Exist

A major limitation is that the results apply only to the populations studied and the defined short time frames. Findings were mixed in some trials comparing Kevindol to other analgesics for specific types of surgery, highlighting that subgroup findings are uncertain. The need for further research exists in areas exploring different study designs in pediatric patients, as well as comorbid groups, where data for certain groups remain insufficient. Research does not determine whether an individual will respond similarly across all contexts; study results reflect the specific conditions under which they were conducted.

Key Studies & References DailyMed Label for Ketorolac Tromethamine

Common questions about Kevindol (FAQ)

---

Q: Does Kevindol require a prescription?

Yes, according to official regulatory documentation, Kevindol is classified as a prescription-only medication. All administration forms, including the injectable, oral tablet, and nasal spray, are subject to a controlled protocol defined in the product information.

Q: What is the main difference between Kevindol and over-the-counter pain relievers?

Kevindol (ketorolac tromethamine) is officially described as a potent non-opioid analgesic used for managing moderate-to-severe pain. Unlike many over-the-counter options, regulatory documents specify that all systemic formulations of Kevindol are provided only under a highly controlled protocol. This protocol includes sequential use and a strict limitation that treatment must not exceed five days in total.

Q: How quickly does Kevindol usually start working?

According to official product information, the onset of the drug's action varies depending on the specific route of administration. The injectable formulation is noted to provide the most rapid analgesic effect.

Q: Is there a risk of dependence or withdrawal associated with Kevindol?

Kevindol is officially defined as a potent non-opioid analgesic. Regulatory documents and safety summaries for this drug do not list dependence, addiction, or withdrawal as risks associated with its authorized short-term use.

Q: Is there a connection between Kevindol and weight gain or loss?

The official safety profile lists edema (swelling or fluid retention) as a common adverse reaction, occurring in 1% to 10% of patients. Changes in body weight outside of this description, such as generalized weight gain or loss, are not frequently cited in the common reaction summaries.

Q: How long does the effect of a single dose of Kevindol typically last?

The official product protocols define specific dosing intervals for both injectable and oral forms. This information indicates the typical time frame of the drug's effect before the next scheduled dose is permitted.

Q: Is it common for people to switch from a different medication to Kevindol?

Official guidelines characterize Kevindol as a robust alternative for managing moderate-to-severe discomfort without relying on opioid agents. Furthermore, the oral tablet is designated solely as a continuation therapy intended to follow initial administration via injection, establishing a specific sequence of use.

Q: Are there any specific foods that should be avoided while on Kevindol?

Official product labeling specifies that the oral tablet formulation is administered with food or an antacid. The regulatory documentation does not generally identify specific foods that are prohibited for consumption while using the medicine.

Q: Can Kevindol be taken with other supplements or vitamins?

Official regulatory documentation regarding interactions primarily focuses on prescription medications, specific NSAIDs, and anticoagulants. The labeling does not typically detail the risk of interactions with common over-the-counter vitamins or general supplements.

Q: If I miss a dose of Kevindol, what should I do?

Official product labeling outlines the strict dosing schedules and maximum daily limits that must be observed for Kevindol. This information emphasizes continuing adherence to the prescribed frequency and strictly avoiding the mandated maximum daily dose.

Q: What are the rules regarding driving or operating machinery while taking Kevindol?

The official safety profile lists central nervous system effects, including dizziness and somnolence (drowsiness), as common adverse reactions. Regulatory documentation requires awareness of these potential effects when performing activities that require full mental alertness, such as driving or operating machinery.

Q: What should I do if I suspect an allergic reaction to Kevindol?

Hypersensitivity, or an allergic reaction, to Kevindol or any other NSAID is a contraindication for using the drug. The official safety information notes that symptoms of a serious reaction warrant immediate medical attention.

Q: Is it okay to stop taking Kevindol suddenly, or should it be tapered?

Kevindol is only authorized for a maximum of five days of combined systemic use. Because of this short restriction on the total treatment duration, official guidelines do not typically detail a required tapering schedule for discontinuation.

Q: Where can I find the official prescribing information for Kevindol?

The complete official prescribing information for Kevindol, which includes the patient leaflet and detailed medical guidance, can be accessed through government regulatory websites. These sources include the FDA and the National Institutes of Health (NIH) DailyMed monograms.

Q: Does Kevindol lose its effectiveness over time (tolerance)?

The clinical research base for Kevindol is restricted to authorized short-term use, typically up to five days. Because of this focus, studies and official regulatory guidance do not address the potential for tolerance (losing effectiveness) to develop over extended periods of time.

Q: Can Kevindol affect birth control or fertility?

Official regulatory documents indicate that, as a class of medication, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may interfere with female fertility. While the drug is contraindicated during labor, the labeling does not typically detail interactions with specific types of hormonal birth control methods.

Q: Are there different brands of the same Kevindol ingredient?

Kevindol is the trade name for the active ingredient ketorolac tromethamine. Regulatory agencies maintain listings of other manufacturers and brand names that contain this same chemical ingredient.

Q: What types of tests might a doctor order before starting Kevindol?

Due to strict contraindications related to organ failure (renal, hepatic, and cardiovascular), official documentation requires special consideration for these populations. Testing may be required to assess the functional status of these systems before or during the course of treatment.

Q: Does Kevindol have interactions with any herbal remedies?

The official interaction documentation primarily focuses on interactions with prescription medications and certain over-the-counter agents. The labeling does not typically detail specific interactions with all available herbal remedies.

Q: Can Kevindol cause an increase in anxiety or mood changes?

The official safety profile lists several nervous system reactions, including headache, dizziness, and drowsiness. Adverse reactions related to mood, such as an increase in anxiety, are typically classified as less common or rare, if documented in the regulatory safety summaries at all.

Q: What is the difference between the immediate-release and extended-release versions of Kevindol?

Regulatory documents list the available dosage forms, which include the oral tablet and the solution for injection. If different release profiles, such as immediate-release (IR) or extended-release (ER) versions of the oral tablet, are approved, they are specified in the official labeling.

Q: Are there specific monitoring requirements while taking Kevindol (e.g., blood tests)?

Official documentation requires specific monitoring when Kevindol is co-administered with certain drugs, such as Lithium and Methotrexate, due to the potential for increased toxicity. Monitoring is also required for patients who have mild-to-moderate renal impairment.

Q: How does the time of day affect when I should take Kevindol?

Official administration instructions define the frequency of dosing and the maximum daily dose. The instructions do not generally specify a preferred time of day (such as morning or evening) for the medication to be taken.

Q: Do Kevindol side effects get better or worse over time?

The official safety profile lists common adverse reactions that may occur during treatment. Due to the maximum five-day duration of use, official regulatory information does not typically contain long-term data on the resolution or persistence of these side effects.

Q: What is the official half-life or duration of action for Kevindol?

Official product information includes specific pharmacokinetic data which describes how the drug is processed by the body. This data includes the half-life and maximum plasma concentration (C max) values, which help characterize how long the active drug remains in the body.

Q: What is the role of Kevindol in treating nerve pain?

The evidence base for Kevindol primarily focuses on treating pain caused by nociceptive signaling and inflammation, such as post-operative or musculoskeletal discomfort. Official regulatory documents authorize the drug for specific acute pain conditions, which may or may not include components of neuropathic (nerve) pain.

Kevindol (ketorolac tromethamine) must be stored and disposed of in strict accordance with the conditions specified in the regulatory labeling.

Storage Conditions

The medication must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and must be protected from both light and excess moisture. The injectable formulation should not be refrigerated or frozen. The product container should be kept tightly closed in the original packaging, and all formulations must be kept out of the sight and reach of children.

Stability and Disposal

The in-use stability of certain forms is time-limited: the Nasal Spray must be discarded within 24 hours of the first dose, and the injection contents must be used immediately after opening. Unused or expired Kevindol must be disposed of in compliance with all local, state, and federal regulations.